331 related articles for article (PubMed ID: 11694786)
1. First-line Herceptin monotherapy in metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
[TBL] [Abstract][Full Text] [Related]
2. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Herceptin and taxanes.
DiƩras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
Cook-Bruns N
Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
[TBL] [Abstract][Full Text] [Related]
5. Role of Herceptin in primary breast cancer: views from North America and Europe.
Leyland-Jones B; Smith I
Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of HER2 in breast cancer.
Piccart M; Lohrisch C; Di Leo A; Larsimont D
Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
[TBL] [Abstract][Full Text] [Related]
7. Dose scheduling--Herceptin.
Leyland-Jones B
Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
Smith IE
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
[TBL] [Abstract][Full Text] [Related]
9. What can we learn from Herceptin trials in metastatic breast cancer?
Bell R
Oncology; 2002; 63 Suppl 1():39-46. PubMed ID: 12422054
[TBL] [Abstract][Full Text] [Related]
10. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials of Herceptin(trastuzumab).
Baselga J
Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
[TBL] [Abstract][Full Text] [Related]
13. Herceptin in early breast cancer: a call for judicious use.
Thorat MA
Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
Sawaki M; Ito Y; Tada K; Mizunuma N; Takahashi S; Horikoshi N; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
Tumori; 2004; 90(1):40-3. PubMed ID: 15143970
[TBL] [Abstract][Full Text] [Related]
15. [Herceptin as a single agent in patients with HER2 overexpressing metastatic breast cancer].
Wang T; Jiang ZF; Song ST; Liu XQ; Yu JX; Liu F; Yan M
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):430-2. PubMed ID: 15355650
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data.
Eiermann W;
Ann Oncol; 2001; 12 Suppl 1():S57-62. PubMed ID: 11521723
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
19. Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting.
Miles DW
Breast Cancer Res; 2001; 3(6):380-4. PubMed ID: 11737889
[TBL] [Abstract][Full Text] [Related]
20. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
Vogel C; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ;
Eur J Cancer; 2001 Jan; 37 Suppl 1():S25-9. PubMed ID: 11167088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]